Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $29.29 Consensus Price Target from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $29.2857.

Several analysts have recently commented on the stock. Guggenheim increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a report on Wednesday, June 24th. BTIG Research restated a “buy” rating and set a $27.00 target price (up from $23.00) on shares of Zevra Therapeutics in a report on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $13.98 on Tuesday. The company has a market capitalization of $826.50 million, a P/E ratio of 7.03 and a beta of 0.85. The business has a 50 day simple moving average of $11.68 and a 200-day simple moving average of $10.00. Zevra Therapeutics has a twelve month low of $7.16 and a twelve month high of $14.58.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The company had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million. Research analysts predict that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in Zevra Therapeutics during the fourth quarter worth approximately $53,000. Russell Investments Group Ltd. raised its holdings in shares of Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning acquired a new position in Zevra Therapeutics in the second quarter worth approximately $92,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Zevra Therapeutics in the second quarter valued at $99,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.